人福医药：拟向控股股东招商生科定增募资不超过35亿元

Core Viewpoint - ST Renfu plans to raise no more than 3.5 billion yuan through a private placement to its controlling shareholder,招商生科, aimed at funding innovative drug research, sexual health, and complex formulation manufacturing base construction, as well as supplementing working capital [1] Group 1 - The private placement will lead to an increase in the company's share capital [1] - The shareholder structure will change, but the proportion of existing shareholders will be affected without altering the controlling shareholder or actual controller [1] - After the issuance,招商生科 will remain the controlling shareholder, ensuring no change in the company's control [1]